Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Cancer Ther ; 18(6): 1149-1157, 2019 06.
Article in English | MEDLINE | ID: mdl-31015311

ABSTRACT

The BRAF V600E mutation and BRAF inhibitor responsiveness characterize ∼50% of patients with the non-Langerhans cell histiocytosis (non-LCH) Erdheim-Chester disease (ECD). We interrogated the non-LCH molecular landscape [ECD, n = 35; Rosai-Dorfman disease (RDD), n = 3; mixed ECD/RDD, n = 1] using BRAF V600E PCR and/or next-generation sequencing [tissue and cell-free DNA (cfDNA) of plasma and/or urine]. Of 34 evaluable patients, 17 (50%) had the BRAF V600E mutation. Of 31 patients evaluable for non-BRAF V600E alterations, 18 (58%) had ≥1 alteration and 12 putative non-BRAF V600E MAPK pathway alterations: atypical BRAF mutation; GNAS, MAP2K1, MAP2K2, NF1, and RAS mutations; RAF1 or ERBB2 amplifications; LMNA-NTRK1 (TRK inhibitor-sensitive) and CAPZA2-BRAF fusions. Four patients had JAK2, MPL ASXL1, U2AF1 alterations, which can correlate with myeloid neoplasms, a known ECD predisposition, and one developed myelofibrosis 13 months after cfDNA testing. Therefore, our multimodal comprehensive genomics reveals clinically relevant alterations and suggests that MAPK activation is a hallmark of non-LCH.


Subject(s)
Cell-Free Nucleic Acids/genetics , Erdheim-Chester Disease/blood , Erdheim-Chester Disease/pathology , Genomics/methods , Histiocytosis, Sinus/blood , Histiocytosis, Sinus/pathology , Adolescent , Adult , Aged , Early Detection of Cancer/methods , Erdheim-Chester Disease/urine , Female , High-Throughput Nucleotide Sequencing , Histiocytosis, Sinus/urine , Humans , Leukemia, Myeloid/diagnosis , Male , Middle Aged , Mitogen-Activated Protein Kinases/genetics , Mutation , Polymerase Chain Reaction , Proto-Oncogene Proteins B-raf/genetics , Young Adult
2.
Oncotarget ; 5(11): 3607-10, 2014 Jun 15.
Article in English | MEDLINE | ID: mdl-25003820

ABSTRACT

Erdheim-Chester disease (ECD) is a rare histiocytosis with a high prevalence of BRAF V600E mutation (>50% of patients). Patients with BRAF-mutant ECD can respond to BRAF inhibitors. Unfortunately, the lack of adequate archival tissue often precludes BRAF testing. We hypothesized that cell-free DNA (cfDNA) from plasma or urine can offer an alternative source of biologic material for testing. We tested for BRAF V600E mutation in cfDNA from the plasma and urine of 6 ECD patients. In patients with available archival tissue, the result of BRAF mutation analysis was concordant with plasma and urine cfDNA results in all 3 patients (100% agreement, kappa 1.00). In all 6 patients, BRAF mutation analysis of plasma and urine cfDNA was concordant in 5 of 6 patients (83% agreement, kappa 0.67). Testing for BRAF V600E mutation in plasma and urine cfDNA should be further investigated as an alternative to archival tissue mutation analysis.


Subject(s)
DNA/blood , Erdheim-Chester Disease/enzymology , Erdheim-Chester Disease/genetics , Mutation , Proto-Oncogene Proteins B-raf/genetics , Adult , Aged , DNA/genetics , DNA Mutational Analysis , Erdheim-Chester Disease/blood , Erdheim-Chester Disease/urine , Female , Humans , Male , Middle Aged , Prognosis , Prospective Studies , Proto-Oncogene Proteins B-raf/blood , Proto-Oncogene Proteins B-raf/urine
SELECTION OF CITATIONS
SEARCH DETAIL
...